Neurocrine Biosciences (NBIX) Cash & Equivalents (2010 - 2026)

Neurocrine Biosciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $266.5 million for Q1 2026.

• Quarterly Cash & Equivalents rose 37.3% year-over-year to $266.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.5 million (up 37.3% YoY) and the FY2025 annual result came in at $713.0 million, up 206.01% from the prior year.
• Cash & Equivalents was $266.5 million for Q1 2026 at Neurocrine Biosciences, down from $713.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $713.0 million in Q4 2025 and bottomed at $103.8 million in Q1 2023.
• A 5-year average of $272.3 million and a median of $264.0 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 61.58% — and 2024, when it jumped 281.79%.
• Neurocrine Biosciences' Cash & Equivalents stood at $270.7 million in 2022, then fell by 4.29% to $259.1 million in 2023, then dropped by 10.07% to $233.0 million in 2024, then surged by 206.01% to $713.0 million in 2025, then sank by 62.62% to $266.5 million in 2026.
• Business Quant data shows NBIX's Cash & Equivalents at $266.5 million in Q1 2026, $713.0 million in Q4 2025, and $340.2 million in Q3 2025.